James Murray
MP for Ealing North · Labour (Co-op) · United Kingdom
“Travellers will not need to do anything differently when using the allowances, but the revised categories change the combinations of products that can be brought into the UK duty-free. The changes were announced at the 2025 Budget and follow a review of travellers’ allowances after our exit from the European Union.”
House of Commons19 October 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“The overall volume of alcohol that individual travellers are allowed to bring back remains the same; it is the categories that different alcohol products fall into that is changing. Where people have previously maximised allowances across separate categories, they may be able to bring back less of those products in total.”
House of Commons19 October 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Secondly, the existing still wine category is replaced by a single wine category covering both still and sparkling wine. Sparkling wine now forms part of the 18-litre wine allowance rather than the separate nine-litre category for drinks of up 22% alcohol by volume.”
House of Commons19 October 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I thank hon. Members for their contributions. I welcome the support of the official Opposition for this measure, and acknowledge the long-standing conversations that the hon. Member for Grantham and Bourne and I have had on different sides of the aisle along Committee corridor.”
House of Commons19 October 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Although individual travellers will not need to do anything differently when using the allowance, the revised categories will have changed the combinations that can be brought into the UK duty-free. The existing 42-litre beer allowance remains unchanged, but cider is now included in that allowance.”
House of Commons19 October 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Some travellers are now able to bring back more of certain products duty-free, while those who previously maximised allowances across separate categories may be able to bring back less of those products in total. However, the overall duty-free allowance remains the same.”
House of Commons19 October 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
The complete record
3,590 held · 3,573 searchable for James Murray. The searchable lines are below in date order, each linked to its source. Free to read, in full, without an account. Page 6 of 10.
This is not an official version of UK Parliament proceedings. It reproduces the published record and links to it; the official version is the one UK Parliament publishes.
“Where there is strong divergence of medical opinion on treatment, the two possible responses are to continue with the uncertainty—and, with that, conflicting opinions and advice—or to undertake a trial, not just to resolve a dispute but to make sure that children with gender-related distress get the same standards of care as everyone else in the NHS. As Dr Cass has said, the vast majority of children and young people who question their gender will resolve it without needing any support other than that of their friends and family. For many young people, questioning their identity on many different fronts is a normal part of growing up, and we should simply let them be. For a small number of young people, though, greater support is needed because of the level and longevity of the discomfort that they feel.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Friend the Member for Ilford North (Wes Streeting), which followed the temporary ban brought in by the previous Government. I do not think there is anyone with more respect as a clinician in this space than Dr Cass, and my predecessors in this role recognised that too. Dr Cass identified treatment for gender incongruence as “an area of remarkably weak evidence”. She found that even clinicians working in the field were divided on the best way to support, treat and care for young people suffering gender dysphoria.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“In 2020, NHS England commissioned leading paediatrician Dr Hilary Cass to carry out a review of NHS gender identity services for under-18s. What Dr Cass uncovered was shocking and scandalous, and she made a series of recommendations for how children could be better protected and supported. I remind the House that those recommendations were accepted in full by both the Conservative Government of the time and my party in opposition. It was, in my mind, clearly wrong for children and young people to be routinely prescribed puberty blockers for gender dysphoria without any clear evidence on their benefits or risks. The situation was out of control, and I fully supported the indefinite ban introduced by my predecessor, my right hon.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I do not believe that children’s safety and wellbeing was being adequately protected just a few years ago. I think it would be helpful to remind Members how we arrived at that point. For several years before the turn of the decade, the number of children and young people being referred for NHS support around their gender identity increased rapidly. Stories subsequently emerged of young people struggling after undergoing radical and permanent transition surgery at a young age, children being rushed into taking medication without adequate therapy beforehand, and clinicians disregarding conditions such as neurodiversity and mental health conditions. As such, there was rightly deep concern about the vulnerability of these children and young people, the care and treatment they were receiving and the surge in referrals.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“With your permission, Madam Deputy Speaker, I shall make a statement on the Pathways trial. I know what a sensitive, emotive and difficult issue this is. I myself have wrestled with, and at times struggled with, the profound challenges that this subject raises. In all of my consideration and deliberation over this matter, my bottom line has been to protect the safety and wellbeing of children and young people. The way to do that is to follow expert clinical advice and take an evidence-led approach, which is what this Government are doing. As adults, we all owe a duty of care to every child and young person in the country. It is a responsibility that I—both as a citizen and as Health Secretary—bear with the utmost seriousness and sincerity.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“As I set out, I feel uncomfortable and uneasy when considering this matter, but I think that the right way for us to move forward is to have the clinical evidence on which to base decisions. I have received reassurances about there being the highest possible level of scrutiny and protection from harm for young people involved in the trial, and that is the basis on which, on balance, I think it is right for it to proceed.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“As I set out, there is intense scrutiny, and there are robust mechanisms to prevent the children involved from being harmed. She mentioned the MHRA recommendation for the lower age limit. Initially, there was no lower age limit, but a scientific dialogue between the MHRA and the trial sponsor led to publication last week of the updated protocol, which recommended the minimum ages of 11 and 12. The gateways to younger people and children becoming involved in the trial are significant. There must be not just consent or assent from the children, and consent from their parents or guardians, but approval from the NHS care team, the national multidisciplinary team and others before anyone can be involved.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I agree with the shadow Minister that most children and young people who are questioning their identity and gender are likely to resolve those questions on their own, and I think Dr Cass would agree with that. As I said in my opening remarks, for the majority of children who question their gender, we should let them be; they will resolve the matter through their friends and family and their own development. We are talking here about a small subset within a small group of children who need further support. I also agree with the shadow Minister that the situation before Dr Cass did her review—the situation that had developed in the last few years before the turn of the decade—was totally unacceptable, and we should be clear that that was wrong. The shadow Minister asked about protecting the young people involved in the trial from harm.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“As my hon. Friend will know, the recommendations in Dr Hilary Cass’s review set out how to establish better services for young people in the future. The focus of today’s statement, the clinical trial, is just one part of the wider work on how best to support young people who need extra support in this situation. It was welcome that there had been, at least until recently, a cross-party consensus that Dr Cass was finding the right way through this difficult matter.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“As I said, a decision to withdraw is triggered by the participant meeting set objective criteria related to the risk of harm.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“As I said earlier, I welcome the changes that it has brought forward to strengthen the criteria, which will lead to greater monitoring and clinical reassessment, and to setting objective criteria for withdrawing children and young people from the trial entirely. The MHRA has been engaged in a scientific dialogue with the trial sponsors, and it was the outcome of that process that led the MHRA, as an independent body, to publish the updated protocol towards the end of last week. Now that that is in place, we have greater reassurance about the safeguards. The trial is expected to involve around 226 children and young people over five and a half years, with each participant potentially being offered puberty blockers for up to 24 months.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I welcome the fact that the hon. Lady agrees with the Government that we should base our decisions about whether and how to provide support for children, particularly in the case of the treatment that is at the centre of this clinical trial, on clinical evidence and the expert advice of clinicians. There can be no one in this field more widely respected than Dr Hilary Cass, whose recommendations form the basis of the decision that we have taken as a Government. The hon. Lady asked about the work of the MHRA since early this year to strengthen the safeguards for young people involved in the trial.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I absolutely agree with my hon. Friend about the importance of following clinical evidence and taking a clinically led and evidence-based approach to this decision. As I said, I have felt uncomfortable and uneasy about some of the challenges raised by this matter, but for me, the right way to move forward is to follow the clinical advice, and to base future decisions on clinical evidence, given that I have received the most robust assurances about the safeguards that are in place to protect young people involved in this trial from harm.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“That is why, although my starting principle is that clinical evidence is the right way to approach such a matter, I wanted that extra reassurance. That is why I asked for the most detailed possible assurances from my clinical advisers, to ensure that those robust safeguards are in place in the way the trial is now designed.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I am sure that the hon. Lady will agree that this is now one of the most heavily scrutinised clinical trials in this country in recent history, and rightly so—it is right that it is so heavily scrutinised and that we all seek assurances about the safeguards in place. It is right that, as Health Secretary, I made sure that I got those detailed safeguards before coming to the House to set out the Government’s position today. The hon. Lady asked how usual it is for the MHRA to work with the sponsors of trials. My understanding is that the MHRA routinely works with trial sponsors to iterate the protocols in relation to those trials. Because this trial involves children and young people, for me, the bar should be exceptionally high, to ensure that those safeguards are in place.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“My hon. Friend raises an important point about the relationship between politics and clinical evidence and clinically led decisions. Being led by clinical advice and clinical evidence is a decision that I and this Government stand behind. In this case, it is a matter where in considering some of the issues raised, I have felt uncomfortable and uneasy, but that commitment to clinical evidence, particularly recommended by someone as widely respected as Dr Cass, is the basis on which we can move forward. As I mentioned in response to the Chair of the Health and Social Care Committee, because this involves children and young people, I wanted to receive extra assurances that the clinical advice was robust and that the safeguards would be as robust as possible.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“The hon. Lady refers, apparently with some certainty, to what she considers to be the clinical outcomes of these puberty blockers on young people. I have to say, with all due respect, that I would trust Dr Cass’s conclusion more than the hon. Lady’s, which is that there is not evidence about the risks or benefits of these medications. That is exactly why Dr Cass was so clear in recommending a trial to find that clinical evidence, because that is the basis on which we can take those decisions.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“As a result of the work that the MHRA has been doing with these trial sponsors in recent months, there are now objective set criteria against which children and young people involved in the trial would be automatically withdrawn. Those criteria, as I set out earlier, will stop the short-term harm, and the view of the National Institute for Health and Care Research is that this means any long-term harm should not occur or go unnoticed. It is important that we ensure that the appropriate safeguards are in place for this trial. That is why I welcome what the MHRA has done in recent months, because it strengthens those safeguards, which are important in any clinical trial but, in this trial, could not be more important.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“The hon. Lady is right to draw attention to some of the gateways that children and young people will have to go through before being accepted on to the trial. That will involve not just the child assenting and the parents giving consent, but the NHS care team and a national multidisciplinary team, which will take into consideration all the different aspects of a child’s life that I set out in my earlier remarks about their health, but also the wider context that the children are coming from. The importance here is to ensure that there is an exceptionally high bar for children and young people taking part in this trial, and that is the process that has now been established.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Let me be absolutely clear, for the avoidance of all doubt, that the Government’s clear expectation is that all relevant organisations will provide the data required to complete the study.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“My hon. Friend asks about the data linkage study, and I apologise to my hon. Friend the Member for North Northumberland (David Smith), who a few seconds ago also asked about that—I did not respond then but can now address both questions together. It is important to understand that the information in the linkage study is much more limited than the detailed information that the research team will be able to collect about the relative benefits and risks of puberty blockers. NHS England is, however, committed to delivering the data linkage study. NHS England, since assuming responsibility for that study, has taken time to ensure that the data is shared by relevant organisations.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Gentleman and I agree on how unacceptable that situation was, and I put on record my thanks to Sir Sajid Javid for commissioning the work by Dr Cass, because it has been such an important piece of work not only to expose what was happening before, but to provide a way forward.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I thank the right hon. Gentleman for his comments, and although he and I come to a different conclusion on this, I do not doubt for a second the sincerity of his motivation in wanting to protect children and young people. I actually agree with him, as I said in my earlier comments, that most young children who are questioning their gender will resolve it on their own—let them be to resolve it. But there is a small subset of children who will need extra support, and within that there is a question about whether for a very small subset of them there might be a benefit to having treatment, and that is what this trial seeks to conclude. I would add that the right hon. Gentleman refers to what happened in the Tavistock clinic and the stories that led to Dr Hilary Cass being commissioned. I think the right hon.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“My hon. Friend rightly points out that the clinical trial—the Pathways study, which is the subject of this statement—is just one part of the wider work being done to make sure that the support is there for children and young people who are questioning their gender and who might, or might not, need support in order to feel well about themselves. The Pathways horizon is an observational study of all children and young people attending NHS children and young people’s specialist gender services. Pathways connect is a brain-imaging study. Pathways voices will interview young people. Horizon intensive is about making sure that there is a comparison group of 300 participants who are expressing gender incongruence but not receiving puberty-suppressing hormones, as my hon. Friend suggested.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I thank the hon. Lady for her remarks, and for her tone and approach to this sensitive matter. Sadly, we have waiting lists across many different parts of the NHS. This Government are determined to deal with that so that everyone can receive the appropriate treatment. There are wider questions, which we could debate at another time, about the support that children who are questioning their identity might need. The focus of today’s statement is specifically on the clinical trial, and it is right that we let that happen. The trial will last five and a half years and it is right that we do that thoroughly, because I do not want this country to be taking decisions in future that are not based on the most solid evidence.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Dr Cass has raised that point a number of times, particularly when she has spoken in public and been interviewed on her concerns about young people accessing equivalent drugs through an unregulated source—through online sources that are not carefully controlled and where there is no monitoring of the effects on young people. That is part of her motivation for recommending the approach that she proposes. As I said earlier, I and the Government want the decisions about what role, if any, such treatments play in the future to be based on the clinical evidence, with the highest possible safeguards in place for children involved in the trials.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Those are the specialisms represented in the national multidisciplinary team, which means that those aspects of the child’s wellbeing are all being considered in that process.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I thank the hon. Lady for her question, which highlights the importance we all place on making sure that vulnerable children are protected in the way that the trial proceeds. Perhaps I can offer her some detail which might reassure her by explaining who is on the national multidisciplinary team. As I mentioned earlier, the national multidisciplinary team will have to give permission for young people to be involved in the trial, as will the NHS care team. That national multidisciplinary team has an independent chair and its membership comprises senior clinicians from a range of clinical backgrounds: paediatric endocrinology, general paediatrics, child and adolescent mental health, clinical nursing, safeguarding, adolescent medicine, allied health and service leadership.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I share my hon. Friend’s disappointment that the cross-party consensus that was in place about the way to approach the issue does not currently seem to be holding. I urge Opposition Members who are not aligned with that cross-party consensus to reconsider their position, because that is the best way forward for our country.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I reassure the hon. Lady, as I set out in my responses to earlier questions, that while my starting point is that clinical evidence should be the basis for our way forward, I have taken the responsibility to interrogate that with the highest level of scrutiny in order to ensure that the conclusions are as robust as possible. That has involved my ensuring that my clinical advisers at the Department for Health and Social Care and the other bodies associated with the Department have provided me with the highest level of detail and reassurance about the safeguards in place. Although I stand behind the principle of following clinical advice and basing conclusions on clinical evidence, I feel that it is important for me, as Health Secretary, to have an extremely high bar for a decision of this magnitude.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Member for South Holland and The Deepings (Sir John Hayes) recognised, and we must never go back to a position where the situation is out of control in the way that it was then. In working out how to move forward, I believe that, as uncomfortable as it may make myself and others on an individual basis, focusing on the principle of following clinical evidence, demanding the highest possible safeguards and protections for the children involved, and setting objective criteria for them to be withdrawn or for action to be taken if the risk of harm increases, is the balanced and correct way to proceed.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Despite our different conclusions on this matter, I respect my hon. Friend. Part of taking decisions as Health Secretary involves sometimes approaching issues where one might feel uncomfortable on a personal level, but none the less being guided by the right principles in order to take decisions for other groups of people in the country and for the country as a whole. I am not in any way disputing how difficult a matter this is; it is one where I, as Health Secretary—and my predecessors—have had to carefully consider how we ensure that the clinical basis for any future decisions is robust and that we can point to it as a foundation for where this matter settles. Before Dr Cass did her review, the situation at the Tavistock clinic was totally unacceptable, as the right hon.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Although the hon. Gentleman comes to a different conclusion from the one that I and the Government have come to, he poses the right question when he asks what harm do we need to protect against while getting clinical evidence. If we are to be led by clinical evidence, it is important to have that evidence in a way that we can rely on, but particularly because it involves children and young people, it is incumbent on us to ensure that the level of protection against the risk of harm is exceptionally high. That is why the strengthening of the protocol announced by the MHRA last week provides that higher level of assurance that I have sought to interrogate and to ensure is there in as robust a way as possible. That gives us the confidence that those safeguards are in place as the trial proceeds.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“The number of expected participants in the trial is 226. That is not a firm target—it does not have to be exactly that number—but that is the number at which statistically significant conclusions can be drawn. The 226 will fall into two camps: one will access the medical treatment immediately and the other will access it after one year. In that way, we will have clinical evidence from which we can draw conclusions and on which we can base future decisions. The number has been chosen so that the evidence can be relied on in the future to take decisions about whether, and if so how, to continue the use of these treatments.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“We are following clinical advice. We are ensuring that there is a triple lock on the consent for children and young people to be involved in this trial, involving the consent or assent of the young person themselves, parents or guardians, and the NHS care team—the national multidisciplinary team that I mentioned earlier. That is how this trial ensures that there is a high bar for being involved in it and that all aspects of a young person’s life are considered before they are approved.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“There is a fundamental difference of approach between me and the hon. Lady. The reason for the trial is not to ensure that young people on the waiting list can get access to treatment; the trial is to find an evidence base on which to take future decisions about whether young people should be offered treatment and, if so, in what way. Talking about waiting lists and the trial combines two things that, in my view of the world, really do not have a relationship in this context.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“This trial has been paused since earlier this year while the MHRA worked to strengthen the safeguards. Those stronger safeguards are now in place, which gives greater protection to young people who are involved in this trial. As I mentioned in my remarks earlier, one of my responsibilities as Health Secretary is to interrogate the detail to ensure that safeguards are adequate. I take that responsibility particularly seriously when it involves children and young people, and that is to ensure that we have the highest possible safeguards against harm of anyone involved in this trial.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“The reason for having this trial is to establish whether there are in fact benefits to this treatment for some children and young people as well as what the risks of harm are. I believe it is right, on balance, to proceed with this clinical trial to get clinical evidence on the basis of having the highest possible protections against a greater risk of harm to children and young people involved in this trial.”
House of Commons22 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Thank you, Mr Speaker. This Labour Government were elected to build an NHS fit for the future. As Secretary of State, I am accelerating modernisation, but health inequalities start long before people access the NHS, so our focus on prevention in the 10-year health strategy is crucial, as is the work of this Government to address wider inequalities, including in housing, air quality and getting more people into work.”
House of Commons9 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“My hon. Friend is absolutely right. Funding must not be held up; it must get to the frontline to help patients, his constituents and people across the country. We are supporting ICBs to work differently with providers to identify and meet the needs of their communities on a new population-based approach. We are also reviewing the outdated GP formula for the distribution of funding to ensure that, for the first time in two decades, it will accurately reflect need and ensure that deprived communities get their fair share.”
House of Commons9 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“My hon. Friend is right to point to the fact that the current model of care works least well for some of those experiencing the greatest disadvantage. I am pleased that we have joint commissioning arrangements of more than £28 million in place between the NHS and Swindon borough council, which will help to tackle issues for those most at risk. As I mentioned in response to the question from my hon. Friend the Member for Camborne and Redruth (Perran Moon), we are reviewing the funding formula for the resources of GP practices for the first time in two decades. That is a crucial step to ensuring that we have a fairer distribution of resources across the country.”
House of Commons9 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I look forward to working constructively with the hon. Lady in her role as the Chair of the Health and Social Care Committee. She is absolutely right to point to the importance of embedding prevention and healthier lifestyles in the way that we approach healthcare in this country. Although we talk a lot and passionately about the NHS, health is not just about the NHS; so many determinants of health start long before people access the NHS. In our 10-year health plan, there is a huge focus on tackling obesity, smoking and ensuring that people have more active and healthier lifestyles, because that is the way to reduce pressure on the NHS and ensure that people across the country live healthier lives.”
House of Commons9 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I thank the hon. Lady for raising the situation in her constituency. For all of us as MPs, our first job is to raise matters that pertain to our constituents, and healthcare is among the most important services that they receive. I will ask my team to look further into the points that she raises and get back to her.”
House of Commons9 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“It is an essential part of our NHS and its founding principles that the NHS is available to all on the basis of need, not their ability to pay. That is a fundamental principle that we in the Labour party support. I know that some Opposition parties have been moving away from that recently and seeking to privatise the provision of our health service and move to an insurance-based model, but Labour Members believe that all people, including children, must get healthcare based on their need rather than their ability to pay.”
House of Commons9 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“I am surprised by the hon. Lady’s remarks, because where a child goes to school should have no bearing on their ability to access NHS services. If she would like to write to me with further details, I would be happy to look into that matter.”
House of Commons9 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“The renewed women’s health strategy was a really important achievement under the previous Secretary of State, which updated the approach of this Government and reflected the differences in healthcare that women too often receive. If I might offer a personal reflection, since I have become Secretary of State, one issue that many women have raised with me is that they do not feel the health service adequately listens to them, takes their pain seriously, or gives them the right pathways to get the treatment they need. That must change, and this Government will change it.”
House of Commons9 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“This Government’s focus on shifting from hospital to community will benefit millions of people and increase access to care. This shift is underpinned by new community diagnostic centres that now deliver faster, more accessible care at 109 sites, 12 hours a day, seven days a week. By 2030, we will have opened 120 new neighbourhood health centres. This expansion will transform community access for those who most need it.”
House of Commons9 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“This may not be the first project initiated under the last Government that has not exactly run ahead at the fastest pace possible. We need to ensure that neighbourhood health provision is delivered as quickly as possible across the country. Our plans to increase the number of neighbourhood health centres will focus on areas with below-average healthy life expectancy, ensuring that rural towns and deprived areas receive help most rapidly. Part of that will involve the shift from hospital to the community to prevent ill health before it occurs, as I mentioned in an earlier response.”
House of Commons9 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“It does sound concerning that that decision has been taken. I urge all councils to work with their local integrated care boards and other parts of the NHS system to ensure that healthcare of that kind is provided in areas where people can access it, as part of our plan to make certain that healthcare is available throughout the country.”
House of Commons9 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗
“Too many men lead too much of their lives in poor health and face barriers to access to health services. We have published England’s first ever men’s health strategy to get men speaking about their physical and mental health, and we are getting on with implementing it. From partnering with the Premier League to investing in the men’s health community fund, we are meeting men where they are, and helping them to lead longer, healthier lives.”
House of Commons9 June 2026Contains Parliamentary information licensed under the Open Parliament Licence v3.0Source ↗